InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,267.84
(
-0.74%
)
US TECH 100
18,150.00
(
-0.43%
)
Dow Jones
39,065.26
(
-1.53%
)
Brent Oil
81.21
(
-0.13%
)
Bitcoin
67,149.18
(
-1.12%
)
Post# of 251927
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119686
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Mufaso post# 250704

Thursday, 05/09/2024 11:51:05 AM

Thursday, May 09, 2024 11:51:05 AM

Post# of 251927
RAPT—(-34%)—ends_clinical_programs_in atopic dermatitis and asthma:

https://finance.yahoo.com/news/rapt-therapeutics-reports-first-quarter-120000252.html

The Company also announced today that it has decided to close and unblind both its Phase 2b clinical trial of zelnecirnon (RPT193) in atopic dermatitis (“AD”) and its Phase 2a trial of zelnecirnon in asthma. Both clinical trials were placed on clinical hold by the FDA in February 2024 based on a serious adverse event of liver failure requiring transplant in one patient in the AD trial.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up